Humana Inc. (NYSE:HUM)‘s stock had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies in a research report issued to clients and investors on Friday, July 14th. They presently have a $246.00 price objective on the insurance provider’s stock. Piper Jaffray Companies’ price target indicates a potential upside of 0.03% from the company’s previous close.
Other equities analysts have also recently issued research reports about the company. Zacks Investment Research raised Humana from a “hold” rating to a “buy” rating and set a $256.00 price target for the company in a report on Monday, May 8th. Deutsche Bank AG assumed coverage on Humana in a report on Wednesday, April 5th. They issued a “hold” rating and a $216.00 price target for the company. Argus raised Humana from a “hold” rating to a “buy” rating and set a $260.00 price target for the company in a report on Friday, June 9th. Oppenheimer Holdings, Inc. assumed coverage on Humana in a report on Thursday, March 30th. They issued an “outperform” rating and a $236.00 price target for the company. Finally, Cantor Fitzgerald upped their price target on Humana from $190.00 to $200.00 and gave the stock a “neutral” rating in a report on Wednesday, April 26th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $241.65.
Humana (HUM) opened at 245.93 on Friday. Humana has a 12-month low of $163.50 and a 12-month high of $251.79. The firm has a 50-day moving average price of $236.19 and a 200-day moving average price of $220.68. The company has a market cap of $35.54 billion, a P/E ratio of 20.23 and a beta of 0.91.
Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.08 by $0.41. The business had revenue of $13.53 billion during the quarter, compared to analysts’ expectations of $13.61 billion. Humana had a return on equity of 15.85% and a net margin of 3.37%. During the same quarter in the previous year, the firm posted $2.30 EPS. On average, analysts forecast that Humana will post $11.40 earnings per share for the current fiscal year.
In related news, VP Heidi S. Margulis sold 1,500 shares of the stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $231.96, for a total value of $347,940.00. Following the completion of the transaction, the vice president now directly owns 8,150 shares in the company, valued at $1,890,474. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Brian P. Leclaire sold 4,971 shares of the stock in a transaction that occurred on Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total value of $1,193,040.00. Following the completion of the transaction, the senior vice president now owns 14,258 shares of the company’s stock, valued at $3,421,920. The disclosure for this sale can be found here. 0.80% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of HUM. Baldwin Brothers Inc. MA raised its position in shares of Humana by 2.7% in the first quarter. Baldwin Brothers Inc. MA now owns 67,441 shares of the insurance provider’s stock valued at $13,902,000 after buying an additional 1,782 shares during the last quarter. Thrivent Financial for Lutherans raised its position in shares of Humana by 6.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 6,065 shares of the insurance provider’s stock valued at $1,235,000 after buying an additional 360 shares during the last quarter. Orbis Allan Gray Ltd raised its position in shares of Humana by 1.3% in the fourth quarter. Orbis Allan Gray Ltd now owns 1,308,615 shares of the insurance provider’s stock valued at $266,997,000 after buying an additional 16,279 shares during the last quarter. ProShare Advisors LLC raised its position in shares of Humana by 15.8% in the first quarter. ProShare Advisors LLC now owns 17,297 shares of the insurance provider’s stock valued at $3,566,000 after buying an additional 2,356 shares during the last quarter. Finally, Capstone Asset Management Co. raised its position in shares of Humana by 2.0% in the first quarter. Capstone Asset Management Co. now owns 16,805 shares of the insurance provider’s stock valued at $3,464,000 after buying an additional 334 shares during the last quarter. Institutional investors own 99.62% of the company’s stock.
About Humana
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
